Free Trial
→ Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___ (From Behind the Markets) (Ad)tc pixel
NASDAQ:CMPX

Compass Therapeutics Q1 2025 Earnings Report

Compass Therapeutics logo
$2.20 +0.13 (+6.28%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Compass Therapeutics EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.12
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Compass Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Compass Therapeutics Announcement Details

Quarter
Q1 2025
Date
5/8/2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Compass Therapeutics' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Compass Therapeutics' Q1 2025 Press ReleasePress Release
(8-K)
Compass Therapeutics' Q1 2025 Quarterly reportQuarterly report
(10-Q)

Compass Therapeutics Earnings Headlines

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ...
May 23 at 1:11 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in-patients-with-advanced-malignancies-treated-in-the-post-checkpoint-inhibitor-setting-at-the-2026-asco-annual-meeting-1036185551
Compass Therapeutics Eyes FDA Meeting, BLA for Tovecimig as Pipeline Updates Near
May 23 at 5:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30795912
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.tc pixel
May 26 at 1:00 AM  |  Brownstone Research (Ad)
Compass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced Malignancies
May 21, 2026  |  quiverquant.comQ
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299774/0/en/compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in-patients-with-advanced-malignancies-treated-in-the-post-checkpoint-inhibitor-setting-at-the-2026-asc.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
May 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-compass-therapeutics-inc---cmpx-302779472.html
See More Compass Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Therapeutics and other key companies, straight to your email.

About Compass Therapeutics

Compass Therapeutics (NASDAQ:CMPX) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells. Both assets have advanced into clinical development, with ongoing studies evaluating safety, pharmacodynamics and preliminary efficacy across multiple tumor types. Compass also maintains a rich preclinical pipeline of next‐generation antibody constructs designed to address checkpoint resistance and immune suppression in solid tumors.

Compass Therapeutics employs an integrated discovery and development model, combining in‐house antibody engineering capabilities with translational science and biomarker analysis. The company collaborates with academic institutions and contract research organizations to streamline the advancement of its molecules from lead optimization through early‐phase clinical trials. This approach supports rapid iteration and selection of candidates with differentiated mechanisms of action.

Founded in 2018, Compass Therapeutics is led by President and Chief Executive Officer Ravi Mohan, Ph.D., whose experience spans immuno-engineering and oncology drug development. While primarily focused on the U.S. market, the company is positioned to pursue global clinical collaborations and strategic partnerships as its clinical programs mature.

View Compass Therapeutics Profile
Earnings Tools